GlassScriptPhysician profile
Matthew D Tucker
NPI 1891158176
$12,287.23
in general payments reported to CMS, 2019-2025
69 companies · $4,090 in 2025
The $4,090 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $131 · 2022: $1,230 · 2023: $3,050 · 2024: $3,786 · 2025: $4,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $49.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,875.76 |
| Education | $49.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $888.50 | 2022-2025 | Darzalex, Talvey, Tecvayli |
| Merck Sharp & Dohme LLC | $779.63 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $659.85 | 2022-2025 | Venclexta, Creon |
| Novartis Pharmaceuticals Corporation | $653.23 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $590.00 | 2022-2025 | Calquence, Imfinzi, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $536.45 | 2022-2025 | Opdivo, Opdualag, Augtyro |
| Genentech USA, INC. | $496.33 | 2022-2025 | Polivy, Venclexta, Tecentriq |
| Pfizer INC. | $494.75 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $402.29 | 2022-2025 | Ninlaro, Fruzaqla, Iclusig |
| Regeneron Healthcare Solutions, INC. | $385.69 | 2021-2025 | Libtayo, Dupixent, Lynozyfic |
| Celgene Corporation | $343.94 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Incyte Corporation | $339.63 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Seagen INC. | $334.14 | 2022-2023 | Tukysa, Adcetris, Padcev |
| Exelixis INC. | $295.81 | 2022-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $262.02 | 2022-2025 |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $243.24 | 2022-2025 | Enhertu, Datroway |
| Glaxosmithkline, LLC. | $215.45 | 2023-2025 | Jemperli, Ojjaara, Zejula |
| Lilly USA, LLC | $215.44 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Octapharma USA, INC. | $214.37 | 2023-2025 | Octagam Immune Globulin (Human) |
| Astellas Pharma US INC | $206.85 | 2023-2025 | Xtandi, Xospata, Padcev |
| Csl Behring | $204.11 | 2024-2025 | Hizentra |
| Deciphera Pharmaceuticals INC. | $178.22 | 2022-2025 | Qinlock, Tgct, Romvimza |
| Genzyme Corporation | $171.04 | 2023-2025 | |
| Eisai INC. | $159.66 | 2022-2025 | |
| Array Biopharma INC | $155.36 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Aveo Pharmaceuticals, INC. | $155.31 | 2023-2025 | Fotivda |
| Ipsen Biopharmaceuticals, INC | $149.34 | 2023-2024 | Onivyde, Somatuline Depot |
| Beone Medicines USA, INC. | $144.26 | 2025 | Brukinsa, Tevimbra |
| Beigene USA, INC. | $138.40 | 2023-2025 | Brukinsa, Tevimbra |
| Sobi, INC | $135.63 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $127.32 | 2022-2024 | Ultomiris, Soliris |
| Kite Pharma, INC. | $119.59 | 2023-2025 | Yescarta |
| Blueprint Medicines Corporation | $113.10 | 2022-2025 | Ayvakit |
| Boston Scientific Corporation | $97.46 | 2024 | |
| Gilead Sciences, INC. | $96.58 | 2024-2025 | Trodelvy |
| Tempus Ai, INC | $95.72 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.52 | 2023-2025 | Gilotrif |
| Pharmacyclics LLC, An Abbvie Company | $86.78 | 2022-2023 | Imbruvica, Epkinly |
| Amgen INC. | $84.91 | 2022-2023 | Blincyto, Kyprolis |
| Pharmaessentia USA Corporation | $75.25 | 2023-2025 | Besremi |
| Pharmacosmos Therapeutics INC. | $72.31 | 2023-2025 | Monoferric |
| Mirati Therapeutics, INC. | $72.00 | 2023-2024 | Krazati |
| Genmab U.S., INC. | $60.78 | 2023-2025 | Epkinly |
| Taiho Oncology, INC. | $58.90 | 2023-2024 | |
| Servier Pharmaceuticals LLC | $58.04 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $57.31 | 2024-2025 | |
| Springworks Therapeutics, INC. | $55.88 | 2024-2025 | Ogsiveo |
| Morphosys, US INC. | $54.87 | 2022-2023 | Monjuvi |
| Adaptive Biotechnologies Corporation | $50.26 | 2024-2025 | Clonoseq |
| Puma Biotechnology, INC. | $50.13 | 2023 | Nerlynx |
| Tersera Therapeutics LLC | $48.77 | 2023 | Xermelo, Zoladex |
| Stemline Therapeutics INC. | $42.28 | 2023-2024 | Orserdu |
| Acrotech Biopharma INC. | $41.77 | 2022-2025 | Beleodaq |
| Apellis Pharmaceuticals, INC. | $38.93 | 2023-2025 | Empaveli |
| Adc Therapeutics America, INC. | $38.85 | 2023-2024 | |
| Rigel Pharmaceuticals, INC. | $38.53 | 2022-2023 | Tavalisse, Rezlidhia |
| Sumitomo Pharma America, INC. | $35.52 | 2023-2025 | Orgovyx |
| Myriad Genetic Laboratories, INC. | $33.52 | 2023-2024 | Precisetumor, Myrisk |
| Iovance Biotherapeutics, INC. | $32.38 | 2024-2025 | Amtagvi |
| Emd Serono, INC. | $31.35 | 2025 | |
| Fennec Pharmaceuticals, INC. | $30.69 | 2025 | Fyarro |
| Chiesi USA, INC. | $28.69 | 2024 | Cleviprex |
| Recordati_rare_diseases_inc. | $24.83 | 2025 | Enjaymo |
| Coherus Oncology, INC. | $21.51 | 2024 | |
| Immunogen, INC. | $16.31 | 2023 | Elahere |
| Epizyme, INC. | $15.55 | 2022 | |
| Accord Healthcare, INC. | $15.50 | 2023 | |
| Karyopharm Therapeutics INC. | $14.45 | 2022 | |
| Agios Pharmaceuticals, INC. | $14.15 | 2025 | Pyrukynd |
Drugs and devices associated with these payments
Keytruda $695Venclexta $409Darzalex $379Opdivo $320Imbruvica $298Talvey $253Reblozyl $247Calquence $242Imfinzi $232Epkinly $231Brukinsa $220Lynparza $220Ninlaro $220Cabometyx $217Octagam Immune Globulin (Human) $214Tecvayli $206Xtandi $206Hizentra $204Scemblix $201Adcetris $195Kisqali $194Jakafi $169Jaypirca $167Elrexfio $162Libtayo $160Fotivda $155Tukysa $154Pluvicto $153Bosulif $152Verzenio $151Monjuvi $150Somatuline Depot $149Onivyde $149Polivy $144Qinlock $135Mektovi $134Braftovi $134Sarclisa $130Enhertu $129Opdualag $129Padcev $125Nubeqa $123Xofigo $123Carvykti $122Tecentriq $121Lenvima $120Ayvakit $116Erleada $114Jemperli $112Rybrevant $110Ojjaara $104Orgovyx $102Yescarta $102Lorbrena $101Ultomiris $86.67Fruzaqla $84.30Columvi $82.97Lunsumio $82.97Talzenna $82.03Stivarga $81.70Vitrakvi $81.70Xalkori $80.05Elahere $78.81Retevmo $77.62Creon $75.30Besremi $75.25Monoferric $72.31Krazati $72.00Pemazyre $71.96Iclusig $63.55Trodelvy $62.63Tevimbra $62.44Inlyta $61.96Doptelet $61.21Comirnaty $59.90Welireg $59.27Inqovi $58.90Lonsurf $58.90Akeega $58.00Zepzelca $57.31Datroway $56.65Ogsiveo $55.88Phesgo $50.80Clonoseq $50.26Gilotrif $44.10Vonjo $43.73Xospata $43.64Dupixent $42.32Orserdu $42.28Piqray $40.33Tgct $39.85Ibrance $39.00Lynozyfic $38.95Empaveli $38.93Tibsovo $38.90Tasigna $35.24Balversa $35.08Tivdak $34.98Augtyro $34.51Xermelo $32.98
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Tucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.